Artios is a leading independent DNA Damage Response (DDR) company focussed on developing first-in-class treatments for cancer. Established in May 2016, the Company is led by an experienced scientific and leadership team with proven expertise in DDR drug discovery. Artios is building a pipeline of next-generation DDR programmes, including through a unique partnership with Cancer Research Technology (CRT), the development and commercialisation arm of Cancer Research UK (CRUK), and with leading DNA repair researchers worldwide. The Company’s investors include SV Life Sciences, M Ventures, Imperial Innovations, Arix Bioscience PLC, CRT Pioneer Fund (managed by Sixth Element Capital), and AbbVie Ventures. Artios is based at the Babraham Institute in Cambridge, UK.
Employees: 51-200
Total raised: $239M
Founded date: 2016
Investors 7
Funding Rounds 2
| Date | Series | Amount | Investors |
| 10.08.2021 | Series C | $153M | Omega Fund... |
| 15.08.2018 | Series B | $86M | - |
Mentions in press and media 28
| Date | Title | Description | Source |
| 28.09.2021 | Artios Doses First Patient in Phase 1/2a Study of Pol? Inhib... | Arix Bioscience PLC (ARIX) Artios Doses First Patient in Phase 1/2a Study of Pol? Inhibitor ART4215 ... | marketscre... |
| 10.08.2021 | Artios announces £110m Series C financing | Artios announces £110m Series C financing 10-08-2021 Artios Pharma Limited, a leading DNA Damage R... | cambridgen... |
| 28.07.2021 | UK's Artios Pharma lands $153M Series C | Biotech startup Artios Pharma has raised $153 million in a round co-led by Omega Funds and TCG X. Th... | pitchbook.... |
| 27.07.2021 | Artios Announces $153 Million (£110 Million) Series C Financ... | • Funding propels Artios’ ability to progress beyond synthetic lethality and to continue the exploit... | svhealthin... |
| 27.07.2021 | Artios Pharma has completed a $153 million series C | Artios Pharma Limited (Artios), a leading DNA Damage Response (DDR) company exploiting a broad DDR-b... | anderapart... |
| 27.07.2021 | IP : Artios Pharma Ltd - Announces $153 Million (£110 Millio... | • Funding propels Artios' ability to progress beyond synthetic lethality and to continue the exploit... | marketscre... |
| 27.07.2021 | Artios raises USD153m in Series C financing | Arix Bioscience PLC (ARIX) Artios raises USD153m in Series C financing 27-Jul-2021 / 07:02 GMT/BST D... | marketscre... |
| 27.07.2021 | Artios Pharma Ltd - Announces $153 Million (£110 Million) Se... | • Funding propels Artios’ ability to progress beyond synthetic lethality and to continue the explo... | ipgroupplc... |
| 27.07.2021 | Artios Announces $153 Million (£110 Million) Series C Financ... | Funding propels Artios’ ability to progress beyond synthetic lethality and to continue the exploitat... | marketscre... |
| 27.07.2021 | Artios raises USD153m in Series C financing -2- | TCG X is a healthcare investment firm dedicated to advancing disruptive medicines and supporting com... | marketscre... |
Show more